Trio N-Terminal RhoGEF Domain Inhibitor, ITX3-CAS 347323-96-0-Calbiochem

C₂₂H₁₇N₃OS

371.45

MFCD02629172

A cell-permeable thiazolo-benzimidazolone compound that inhibits Trio N-terminal RhoGEF domain- (TrioN) mediated RhoG activation (IC₅₀ = 76 µM) and effectively reduces cellular Rac activation (by 80% with 50 µM ITX3) caused by TrioN, but not GEF337 (RhoA GEF), Tiam1 (Rac GEF), or Vav2 (Rac1/RhoA/Cdc42 GEF), overexpression in HEK293T cells. Culture treatment of ITX at 100 µM is shown to reduce NGF-induced neurite outgrowth of rat PC12 pheochromocytoma cells by 50% and block the formation of multinucleated myotubes by 78% in C2C12 mouse myoblasts cultures induced for differentiation, while the differentiation-associated Myogenin and Troponin T expressions in Trio knock-down C2C12 cells are not affected by ITX at the same concentration.

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Bouquier, N., et al. 2009. Chem. Biol.16, 657.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥95% (HPLC)

solid

Calbiochem^®

OK to freeze
protect from light

yellow

DMSO: 2 mg/mL

ambient

2-8℃

Packaged under inert gas

11 - Combustible Solids

WGK 3